1SXP SCHOTT Pharma AG & Co. KGaA

24.79USD22.60 EUR · XETRA0.00%Mkt Cap: 3.73B USDP/E: 25.11

SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a g…

Institutional holders10 on file

Key Statistics

Company
Market Cap3.73B USD
Enterprise Value4.01B USD
Revenue (TTM)1.12B USD
Gross Profit364.65M USD
Net Income (TTM)160.63M USD
Revenue/Share7.39 USD
Last Price24.79 USD
Fiscal Year EndSep 2025
MR QuarterJun 2026
Employees5.0K
CountryDE
SectorHealthcare
IndustryMedical Instruments & Supplies
ISINDE000A3ENQ51
Valuation
P/E (Trailing)25.11
P/E (Forward)20.63
PEG—
EV/EBITDA14.68
EV/Revenue3.60
P/S3.35
P/B3.39
EPS (TTM)0.99 USD
EPS (Forward)1.20 USD
52W Range
13.8473% of range28.74
52W High28.74 USD
52W Low13.84 USD
Profitability
Gross Margin33.71%
Oper. Margin16.45%
EBITDA Margin24.52%
Profit Margin14.85%
ROE16.42%
ROA9.16%
ROIC15.39%
ROCE16.33%
Growth
Revenue Growth10.00%
Earnings Growth-13.30%
Cash Flow & Leverage
Operating CF197.34M USD
CapEx (TTM)158.77M USD
FCF Margin-1.94%
FCF Yield-0.58%
Net Debt310.81M USD
Net Debt/EBITDA1.14
Net Debt/FCF—
Balance Sheet
Debt/Equity0.09
Current Ratio1.61
Quick Ratio0.74
Book Value/Sh7.32 USD
Cash/Share0.18 USD
Dividends
Fwd Div Rate0.20 USD
Trail. Div Rate0.20 USD
Div. Yield0.80%
5Y Avg Yield—
Payout Ratio20.00%
Ex-Div DateFeb 4, 2026
Pay Date—
Analyst Consensus
Rating2.1 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)27.45 USD
Upside (mean)+10.8%
Target Range18.97 USD – 32.03 USD
18.97+10.8% to mean32.03
# Analysts13
Ownership
Shares Out.150.61M
Float34.35M
Insiders77.00%
Institutions20.29%
Technical
SMA 5026.26 (-5.6%)
SMA 20020.90 (+18.6%)
Beta0.86
S&P 52W Chg12.00%
Avg Vol (30d)86.23K
Avg Vol (10d)114.42K
Technical Indicators
RSI (14)42.8
MACD-0.5893
MACD Signal-0.5703
MACD Hist.-0.0190
BB Upper29.22 USD
BB Middle25.58 USD
BB Lower21.93 USD
BB Width28.52%
ATR (14)0.8453 USD
Vol Ratio (20d)0.34x

About SCHOTT Pharma (ETR: 1SXP)

›

SCHOTT Pharma (ETR: 1SXP) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 5,002 employees.

The shares were at 22.60 EUR on 19 November 2026, up 24.8% over 52 weeks. Its 52-week range is 12.62 EUR to 26.20 EUR: the price is 13.7% below the high and 79.1% above the low.

At a market capitalisation of 3.40B EUR, it trades at 25.1 times trailing earnings and 20.6 times forward earnings. The median trailing P/E of its 19 largest Medical Instruments & Supplies peers is 49.2, a discount of 49% for 1SXP. It pays a dividend yielding 0.80% (it pays out 20% of its earnings), against a median of 0.93% among the dividend payers in that peer group.

SCHOTT Pharma reports return on equity of 16.4%, an operating margin of 16.4% and revenue up 10.0% year over year.

Its debt exceeds its cash by 283.38M EUR, a debt-to-equity ratio of 0.09. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 13 analysts cover the stock, with an average rating of Buy; their mean price target of 25.03 EUR is 10.8% above the current price. The next earnings report is expected on 10 December 2026.